Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 6:51 PM
Ignite Modification Date:
2025-12-24 @ 6:51 PM
NCT ID:
NCT00002757
Eligibility Criteria:
DISEASE CHARACTERISTICS:
* One of the following diagnoses:
* Newly diagnosed B-cell non-Hodgkin's lymphoma in Revised European-American Lymphoma (REAL) categories II 9, 10, and 11, i.e.:
* Diffuse large cell
* Burkitt's
* High-grade B-cell, Burkitt's-like
* L3 leukemia with greater than 5% blasts in bone marrow
* No anaplastic large cell Ki1-positive lymphomas
* Immunophenotype and Murphy stage required prior to randomization
PATIENT CHARACTERISTICS:
Age:
* Over 6 months to under 21 years
* Maximum age 18 years in France and the United Kingdom
Other:
* No congenital immunodeficiency
* No prior organ transplantation
* No prior malignancy
* Not HIV positive
* Available for at least 36 months of follow-up
PRIOR CONCURRENT THERAPY:
Biologic therapy:
* Not specified
Chemotherapy:
* No prior chemotherapy
Endocrine therapy:
* Steroids initiated no more than 72 hours prior to entry allowed
* Bone marrow and cerebrospinal fluid examination required prior to steroids
Radiotherapy:
* Emergency radiotherapy initiated no more than 72 hours prior to entry allowed
Surgery:
* Not specified
Healthy Volunteers:
False
Sex:
ALL
Maximum Age:
20 Years
Study:
NCT00002757
Study Brief:
Protocol Section:
NCT00002757